Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression
Open Access
- 19 February 2008
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 105 (7), 2640-2645
- https://doi.org/10.1073/pnas.0712185105
Abstract
The secreted Bv8 protein has been recently characterized as a regulator of myeloid cell mobilization and a neutrophil-derived mediator of tumor angiogenesis in several xenografts, but its role in tumor progression in an endogenous setting was unknown. The rat insulin promoter (RIP)–T-antigen (Tag) is a well characterized transgenic mouse model of multistage pancreatic β-cell tumorigenesis. Also, the role of neutrophils in RIP-Tag angiogenic switching, as assessed by systemic ablation using anti-Gr1 antibodies at different stages of tumor progression, has been recently described. Here, we show that early treatment of RIP-Tag mice with anti-Bv8 antibodies resulted in a significant reduction in the number of angiogenic islets relative to control antibody-treated mice, implicating Bv8 in the angiogenic switch during neoplasia. Histological analysis showed a significant reduction in vascular surface areas in hyperplastic and angiogenic lesions in pancreatic islets from anti-Bv8-treated mice. Anti-Bv8 treatment also inhibited the mobilization and homing of CD11b+Gr1+ cells to the peripheral blood and the emerging neoplastic lesions. However, anti-Bv8 treatment had no effect on tumor vascularization or burden when initiated at later stages of tumor progression. The stage-dependent efficacy of anti-Bv8 treatment appears remarkably similar to that reported after neutrophil ablation, suggesting that Bv8 is an important mediator of neutrophil-dependent angiogenesis in this transgenic model. In summary, our studies verify a role for Bv8 in the mobilization and recruitment of myeloid cells and in the induction of tumor angiogenesis in the early stages of neoplastic progression.This publication has 36 references indexed in Scilit:
- Bv8 regulates myeloid-cell-dependent tumour angiogenesisNature, 2007
- Endocrine gland–derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesisNature Medicine, 2002
- Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleusNature, 2002
- Identification and Molecular Characterization of Two Closely Related G Protein-coupled Receptors Activated by Prokineticins/Endocrine Gland Vascular Endothelial Growth FactorPublished by Elsevier BV ,2002
- Isolation and identification of EG-VEGF/prokineticins as cognate ligands for two orphan G-protein-coupled receptorsBiochemical and Biophysical Research Communications, 2002
- VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesisCancer Cell, 2002
- Characterization of Endocrine Gland-derived Vascular Endothelial Growth Factor Signaling in Adrenal Cortex Capillary Endothelial CellsPublished by Elsevier BV ,2002
- Identification of an angiogenic mitogen selective for endocrine gland endotheliumNature, 2001
- Identification of Two Prokineticin cDNAs: Recombinant Proteins Potently Contract Gastrointestinal Smooth MuscleMolecular Pharmacology, 2001
- MIT1, a black mamba toxin with a new and highly potent activity on intestinal contractionFEBS Letters, 1999